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Prescribing patterns of evidence-based heart failure 
pharmacotherapy and outcomes in the ASIAN-HF registry: 
a cohort study
Tiew-Hwa K Teng, Jasper Tromp, Wan Ting Tay, Inder Anand, Wouter Ouwerkerk, Vijay Chopra, Gurpreet S Wander, Jonathan JL Yap, 
Michael R MacDonald, Chang Fen Xu, Yvonne MF Chia, Wataru Shimizu, ASIAN-HF investigators*, A Mark Richards, Adriaan Voors, Carolyn SP Lam
Summary
Background Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), β blockers, 
and mineralocorticoid receptor antagonists (MRAs) are of proven benefit and are recommended by guidelines for 
management of patients with heart failure and reduced ejection fraction (HFrEF). We aimed to examine the first 
prospective multinational data from Asia on prescribing patterns of guideline-directed medical therapies and analyse 
its effect on outcomes.
Methods In the prospective multinational ASIAN-HF registry (with enrolment from 46 centres in 11 countries in 
Asia), we enrolled patients aged 18 years or older, with symptomatic heart failure (stage C, with at least one episode of 
decompensated heart failure in the past 6 months that resulted in admission to hospital or was treated in an outpatient 
clinic) and left ventricular systolic dysfunction (ejection fraction ≤40% on baseline echocardiography, consistent with 
2016 European Society of Cardiology guidelines). We excluded patients with heart failure caused by severe valvular 
heart disease, life-threatening comorbidity with a life expectancy of less than 1 year, who were unable or unwilling to 
give consent, or who had concurrent participation in a clinical trial. Patients were followed up for 3 years for the 
outcomes of death and cause-specific admittance to hospital. Primary outcomes were uptake of guideline-directed 
medical therapies (as proportions) by therapeutic class, achieved doses as proportions of guideline-recommended 
doses, and their association with 1-year composite outcome of all-cause death or admittance to hospital because of 
heart failure. This study is registered with ClinicalTrials.gov, number NCT01633398.
Findings Between Oct 1, 2012, and Dec 31, 2015, we enrolled 5276 patients with HFrEF (mean age 59·6 years 
[SD 13·2], 77% men, body-mass index 24·9 kg/m² [5·1], 33% New York Heart Association class III or IV). Follow-
up data were available for 4544 (90%) of 5061 eligible patients taking medication for heart failure, with median 
follow-up of 417 days (IQR 214–735). ACE inhibitors or ARBs were prescribed to 3868 (77%) of 5005 patients, 
β blockers to 3975 (79%) of 5061, and MRAs to 2998 (58%) of 5205, with substantial regional variation. Guideline-
recommended dose was achieved in only 17% of cases for ACE inhibitors or ARB, 13% for β blockers, and 29% 
for MRAs. Country (all three drug classes), increasing body-mass index (ACE inhibitors or ARBs and MRAs), and 
in-patient recruitment (ACE inhibitors or ARBs and β blockers) were associated with attainment of guideline-
recommended dose (all p<0·05). When adjusted for indication bias, increasing drug doses, from low dose 
(1–<25% of guideline-recommended dose) upwards were associated with lower hazards of a 1-year composite 
outcome for ACE inhibitors or ARBs and β blockers compared with non-users. The lowest adjusted hazards were 
in the group that attained guideline-recommended doses above 50% (hazard ratio [HR] 0·54, 95% CI 0·50–0·58 
for ACE inhibitors or ARBs [50–99·9%]; HR 0·47, 0·46–0·50 for β blockers, and HR 0·77, 0·72–0·81 for 
MRAs [≥100%]).
Interpretation Guideline-directed medical therapies at recommended doses are underutilised in patients with HFrEF. 
Improved uptake and uptitration of guideline-directed medical therapies are needed for better patient outcomes.
Funding National Medical Research Council (Singapore), A*STAR Biomedical Research Council ATTRaCT program, 
Boston Scientific Investigator Sponsored Research program, and Bayer. 
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND 
4.0 license.
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Introduction
Current evidence-based guidelines for best practice1,2 
recommend that patients should be treated to trial-
directed doses for angiotensin-converting enzyme (ACE) 
inhibitors or angiotensin receptor anta gonists (ARBs) 
and β blockers, as first-line therapy, and mineralocorticoid 
receptor antagonists (MRAs), as second-line therapy, in 
the management of patients with heart failure with 
reduced ejection fraction (HFrEF). Despite this, many 
patients with heart failure either do not receive these 
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guideline-directed medical therapies or receive doses 
considerably below the guideline-recommended doses.3–5 
A pan-European study reported that there was widespread 
underdosing of ACE inhibitors or ARBs and β blockers 
despite encouraged uptitration. Undertreatment with 
doses that are less than 50% of guideline-recommended 
dose for ACE inhibitors or ARBs and β blockers is 
associated with poorer prognosis.6,7
In Asia, rapidly ageing demographics and the increasing 
prevalence of cardiovascular diseases and metabolic 
disorders are driving an epidemic of heart failure.8 Adding 
to the complexities of the heterogeneous populations, 
emerging data suggests heightened sensi tivity to, and 
pharmacokinetic variability of, cardiovascular drugs in 
patients from Asia.9–12 This background, to gether with 
smaller body size and weight, explains why prescribed 
doses are lower for Asians than they are for their western 
counterparts.9,13–15 Prospective multi national data from 
Asia on prescribing patterns of guideline-directed medical 
therapy and association of doses with outcomes have, 
thus far, been scarce. We studied prescribing patterns of 
evidence-based heart failure pharmacotherapy and their 
association with clinical outcomes in a population with 
heart failure from a large region in Asia.
Methods
Study design and participants
The ASIAN-HF registry, as previously described,16,17 is a 
contemporary prospective multinational registry of 
patients in Asia aged 18 years or older, with symptomatic 
heart failure (stage C, with at least one episode of 
decompensated heart failure in the past 6 months that 
resulted in admission to hospital or was treated in an 
outpatient clinic) and left ventricular systolic dysfunction 
(ejection fraction ≤40% on baseline echocardiography, 
consistent with 2016 European Society of Cardiology 
guidelines1). We excluded patients with heart failure 
caused by severe valvular heart disease, life-threatening 
comorbidity with life expectancy of less than 1 year, who 
were unable or unwilling to give consent, or who had 
concurrent participation in a clinical trial. Patients who 
met eligibility criteria and provided informed consent 
were enrolled from 11 countries in Asia (South Korea, 
Japan, Taiwan, Hong Kong, China, India, Thailand, 
Research in context
Evidence before this study
We searched Medline and EMBASE from Jan 1, 1985 up to the 
start of ASIAN-HF (Oct 1, 2012) for relevant articles published in 
English on prescribing patterns and doses of evidence-based 
medications for heart failure with reduced ejection fraction 
(HFrEF) in Asia or Asians. Search terms were “heart failure” AND 
“medications” OR “therapy” AND “doses” OR “target dose” OR 
“up-titration” OR “titration” AND “Asians” OR “Asia”. We did an 
additional search for each therapeutic class using 
“angiotensin-converting enzyme (ACE) inhibitors”, “angiotensin 
receptor blockers (ARBs)”, “beta-blockers”, and “mineralocorticoid 
receptor antagonists (MRAs)” in place of “medications” or 
“therapy”. We found no cohort studies on prescribing patterns and 
doses of guideline-directed medical therapy for heart failure across 
multinational regions within Asia. We found no such studies when 
we extended the search to March 31, 2017. The search showed a 
scarcity of evidence from Asia, with only ten relevant studies, 
which were mainly small, single-centre studies. There are few data 
on Asian ethnicities from randomised controlled trials. In the 
TRANSCEND and ONTARGET trials, Asians, despite having a lower 
body-mass index than non-Asians, tolerated both telmisartan 
(80 mg/day) and ramipril (10 mg/day) better than did non-Asians. 
Similarly, higher dose controlled-release carvedilol (40 mg/day), 
when compared with 20 mg/day immediate-release carvedilol, 
was safe and well tolerated in a separate small Japanese study. 
Studies have also showed that bisoprolol fumarate (even at half 
the targeted doses) and low dose (5 mg/day) carvedilol had 
beneficial effects in Asians with heart failure and left ventricular 
systolic dysfunction. A comparison study of the pharmacokinetics 
and pharmacodynamics of oral perindopril in normotensive 
Chinese and Caucasian volunteers showed that time to maximum 
concentration after 4 mg was administered was significantly 
shorter for the Chinese subgroups than it was for the Caucasian 
subgroups. Similarly, Cmax and the area under the curve were 
increased after 4 mg was given to the Chinese participants, who 
had lower mean bodyweight than did the Caucasian participants.
Added value of this study
This study is the first prospective, multinational registry of 
real-world data on prescription patterns and doses attained of 
guideline-directed medical therapies in patients with HFrEF 
across most of Asia (11 regions). In the absence of such 
evidence in large multinational Asian populations, the current 
analysis represents the best available evidence for clinicians 
treating HFrEF in Asia. We acknowledge causality, including 
drug efficacy, cannot be established from observational studies, 
which require evidence from randomised controlled trials for 
definitive answers.
Implications of all the available evidence
There is striking regional variation in the patterns of prescription 
and dosage of ACE inhibitors or ARBs, β blockers and MRAs for 
HFrEF across Asia. Gaps in the administration of guideline-directed 
medical therapy were monotherapy (only ACE inhibitors, ARB, or 
β blocker prescribed instead of combined therapy) and widespread 
underdosing. The scientific literature increasingly points to an 
earlier onset of heart failure in Asian than in western populations. 
With pharmacotherapy being the mainstay in the management of 
heart failure, our findings have major implications for clinicians, 
health policy makers, and health-care providers, and support 
active advocacy for the conscientious initiation and uptitration of 
evidence-based medications to improve the outcomes of patients 
in Asia with HFrEF.
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Malaysia, Philippines, Indonesia, and Singapore) at diff-
erent stages of economic development.
We recruited participants between Oct 1, 2012, and 
Dec 31, 2015. At investigation sites (46 in total with 
>220 investigators), which included medical, cardiology, 
and specialty heart failure units, patients with acute heart 
failure were admitted and patients with chronic heart 
failure were followed up as outpatients. Sites in 
ASIAN-HF were selected on the basis of the size of the 
country, geographical location of the site within the 
country, patient population served, heart failure patient 
volume, and availability of expertise in echocardiography.17 
We included a mix of private and public hospitals and 
tertiary, university, and specialist cardiovascular hospitals 
in capital cities and provincial cities (appendix). 
Consecutive patients at each site were screened to 
determine eligibility based on inclusion and exclusion 
criteria.17 Screening logs were encouraged but were 
not available from all sites. Every effort was made to 
ensure protocol standardisation and adherence, including 
translation of languages specific to each region, on-site 
investigator training, regular monitoring (both in-person 
and remote), and centralised database management.
Ethics approvals were obtained from the local insti-
tutional review committee of each participating centre and 
all participants gave informed consent. The establish ment 
of the registry and this study conform to the ethical 
guidelines in the Declaration of Helsinki.
Data collection and medications
Demographic and clinical data were collected at baseline, 
including socioeconomic status, clinical signs and 
symptoms, functional status, date of diagnosis with heart 
failure, duration of heart failure, prior cardiovascular 
procedures or investigations, clinical and lifestyle risk 
factors, medical history, comorbidities, quality of life, 
blood chemistry, standard 12-lead ECG, and transthoracic 
echocardiography. Patients were followed up for 3 years 
for the outcomes of death and cause-specific admittance 
to hospital. Causes of death or admittance to hospital were 
adjudicated by a central event adjudication committee 
using prespecified criteria.
Case report forms included a complete record of all 
concomitant medications, dosage patterns, maximum 
doses achieved (yes or no, based on assessment by 
investigators), reasons if not achieved (eg, side-effects or 
intolerance, still uptitrating, cost, and other, with a text 
field). Medications were identified by therapeutic class, 
including ACE inhibitors, ARBs, β blockers, MRAs 
(appendix), and others (digoxin, ivabradine, and loop and 
thiazide diuretics). Data on patients’ medication were 
collected at baseline and throughout the follow-up 
period, including changes in drugs and doses. Maximum 
total daily doses attained during follow-up were calculated 
as a percentage of the guideline-recommended doses 
for daily maintenance of the individual heart failure 
medications (appendix). Doses were grouped into 
categories (0%, 1–24%, 25–49%, 50–99%, and ≥100%) on 
the basis of similar proportions in each of these categories 
and the predominance of doses that are less than 50% of 
the guideline-recommended doses.
Outcomes
Primary outcomes were uptake (as proportions) by 
therapeutic class, achieved doses as a proportion of 
guideline-recommended dose, and their association with 
1-year composite outcome of all-cause death or admittance 
to hospital because of heart failure. 1-year all-cause 
mortality, cardiovascular-related deaths, and admittance to 
hospital because of heart failure were secondary outcomes.
Statistical analysis
We analysed data from each of the five groups (separated 
by percentage of guideline-recommended dose) using 
standard descriptive statistics including, as appropriate, 
mean plus standard deviation and median plus inter-
quartile ranges or numbers and proportions. We tested 
differences between groups using the Kruskal-Wallis test 
(for continuous variables) or the χ² test (for categorical 
variables), and the Cochran-Armitage test for linear 
trends across the ordinal categories of percentage of 
guideline-recommended dose.
To correct for treatment indication bias in outcome 
analysis, all analyses for the effects of successful 
uptitration of ACE inhibitors or ARB, β blockers, and 
MRAs were inversely weighted for the probability of 
receiving the given treatment. We defined successful 
uptitration as the achievement of at least 100% of 
the dose recommended by the European Society of 
Cardiology.1 We modelled the probability of achieving 
uptitration for a particular treatment in a given patient by 
logistic regression using lasso penalisation to obtain 
parsimonious logistic models comprising a few predictor 
variables derived from an initial comprehensive list of 
29 clinical variables (appendix). To find the optimal 
lambda in our lasso regression, we performed ten cross 
validations to increase robustness.18,19
We imputed missing data via random forest regression 
models in the MICE package using the R statistical 
program (version 3.2.4).20 Five imputed datasets were 
created. We did 10-fold cross validation to ensure optimal 
penalty parameters and used all analyses for each imputed 
dataset. Final probability weights were calculated by the 
mean per patient across imputation sets. We used 
multivariable Cox regression models to examine the 
association of percentage of guideline-recommended dose 
prescribed (0%, 1–24%, 25–49%, 50–99%, ≥100%) by 
therapeutic class with a 1-year composite outcome of all-
cause mortality or admittance to hospital because of heart 
failure, with 0% (non-users) as the reference. We also 
analysed the interaction of dose categories by medication 
class and geographical blocs (northeast, south, and 
southeast Asia) with a composite outcome. We checked 
the proportionality hazards assumption for Cox models 
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using statistical tests and graphical diagnostics on the 
basis of the Schoenfeld residuals. The Cox multivariable 
and logistic regression models were restricted to the same 
set of reduced variables, with a minimum of ten events for 
each variable in the model.21,22
Since hypotension, bradycardia, and renal dysfunction 
often restrict the achievement of guideline-recommended 
dose in clinical practice,1 we did a subgroup analysis (with 
or without hypotension [defined as systolic blood pressure 
<90 mm Hg, diastolic blood pressure <60 mm Hg], 
bradycardia [defined as heart rate <60 bpm], and renal 
disease) to examine usage and dosage patterns of ACE 
inhibitors or ARBs, β blockers, and MRAs. 
We did sensitivity analyses using 100% guideline-
recommended dose as a reference, and did additional tests 
confined to data from patients recruited as outpatients and 
assessed associations between achievement of guideline-
directed medical therapies doses and the combined 
outcome of all-cause mortality and admittance to hospital 
because of heart failure. Multiple imputation might 
introduce bias depending on the model.23 Although 
multiple chained equations provide for an effective tool to 
account for missing data, bias cannot be excluded. 
Therefore, we did additional sensitivity analyses, in which 
we analysed our non-imputed data separately, to account 
for this potential bias.
We used Stata version 14 (Stata Corp, College Station, 
TX, USA) and R statistical program (version 3.2.4) for all 
statistical analyses. All p values are two-sided, with a 
5% significance level.
Role of the funding source
The funders of the study had no role in study design, site 
selection, data collection, data analysis, data interpretation, 
or writing of the report. The corresponding author had 
full access to all the data in the study, takes responsibility 
for the integrity of the data and the accuracy of the data 
analysis, and had final responsibility for the decision to 
submit for publication. 
Results
Between Oct 1, 2012, and Dec 31, 2015, we enrolled 
5276 patients with HFrEF (mean age 59·6 years [SD 13·2], 
77% men). The mean left ventricular ejection fraction 
(LVEF) was 27% (7), 33% were New York Heart Association 
(NYHA) class III or IV, and mean BMI was 24·9 kg/m² 
[5·1]). 5061 (96%) of 5276 were prescribed at least one 
class of guideline-directed medical therapies. ACE 
inhibitors or ARBs were prescribed to 3868 (77%) of 
5005 patients, β blockers to 3975 (79%) of 5061, and 
MRAs to 2998 (58%) of 5205, digoxin to 1464 (31%) of 
4763, ivabradine to 447 (10%) of 4585, and loop and 
thiazide diuretics to 4221 (83%) of 5067.
China had the lowest uptake for ACE inhibitors or ARBs 
(286 [60%] of 477), but had the highest uptake for MRAs 
(372 [78%] of 477; figure 1). Indonesia had the highest 
uptake for ACE inhibitors or ARBs (236 [87%] of 272) and 
the lowest uptake of β blockers (167 [61%] of 272). The 
guideline-recommended combination of ACE inhibitors 
or ARB and β blockers was prescribed in only 2914 (55%) 
of the overall ASIAN-HF cohort (5276). The high-income 
countries—for example, Singapore (757 [71%] of 1066), 
Hong Kong (35 [70%] of 50), Korea (207 [65%] of 317), and 
Japan (340 [63%] of 540), but not Taiwan (127 [46%] of 
274)—were more likely to prescribe the dual first-line 
medications than were lower income countries (p<0·001). 
In China, however, 317 (66%) of 477 patients received the 
combination therapy of β blockers with MRA.
Only 127 (2%) of the cohort (5276) had hypotension and 
324 (6%) had bradycardia; 442 (11%) of 4187 patients with 
measurements of serum creatinine or estimated 
glomerular filtration rate (eGFR) at baseline had severe 
renal dysfunction (including renal failure). The difference 
in the proportions of participants achieving the guideline-
recommended doses for ACE inhibitors or ARB or 
β blockers was not significant in patients with hypo-
tension (vs no hypotension, p=0·834 for ACE inhibitors 
or ARBs; p=0·830 for β blockers) or bradycardia (vs no 
bradycardia, p=0·380 for ACE inhibitors or ARBs; 
p=0·224 for β blockers), probably because of the small 
numbers of patients. However, patients with severe 
chronic kidney disease (eGFR <30 mL/min per 1·73 m²) 
and renal failure (eGFR <15 mL/min per 1·73 m²) had 
reduced uptake of ACE inhibitors or ARBs and MRAs 
(both p<0·001). For β blockers, only those with renal 
failure had decreased uptake. In general, as expected, 
fewer patients with severe chronic kidney disease or 
renal failure achieved the guideline-recommended dose 
than did those with less severe disease.
Considerable underdosing of ACE inhibitors or ARBs, 
β blockers, and MRA was observed (figure 2). 
Recommended doses of ACE inhibitors or ARBs were 
reached in only 17% of patients, compared with 13% for 
β blockers, and 29% for MRAs. Reasons given for not 
achieving the guideline-recommended dose included 
already at maximum tolerated dose (2414 [57%] of 4231 
patients), still considering uptitration (986 [23%]), and 
Figure 1: Regional variation in uptake
ACE=angiotensin-converting enzyme. ARB=angiotensin receptor blockers. MRA=mineralocorticoid receptor 
antagonists.


















ACE inhibitors or ARBs β blockers MRA
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side-effects or intolerance (831 [20%]). Cost was not 
reported as a reason for not achieving the guideline-
recommended dose. In those whom the maximum 
tolerated dose was achieved, the median doses against the 
guideline-recommended dose were 50% (IQR 25–100%) 
for ACE inhibitors, 33% (IQR 25–50%) for ARBs, 25% 
(13–50%) for β blockers, and 80% (50–100%) for MRA. 
The median doses against the guideline-recommended 
dose for ACE inhibitor and MRA were comparatively 
higher than that in the overall cohort.
Patient characteristics, stratified by dose, are given in 
the table. Country (all three drug classes), increasing 
body-mass index (ACE inhibitors or ARBs and MRAs), 
and in-patient recruitment (ACE inhibitors or ARBs) 
were associated with attainment of guideline-recom-
mended dose (all p<0·05; appendix). Other independent 
factors associated with attainment of 100% guideline-
recommended dose by therapeutic class are summarised 
in the appendix.
The most commonly prescribed ACE inhibitors were 
enalapril (716 [30%] of 2422 patients on ACE inhibitors), 
perindopril (691 [29%]), and ramipril (687 [28%]), 
accounting for 57% (2094 of 3653) of all evidence-based 
ACE inhibitors or ARB used. Losartan potassium (429 
[32%] of 1349 patients on ARBs), valsartan (425 [32%]), 
and candesartan cilexetil (300 [22%]) were the most com-
monly prescribed ARBs, accounting for 32% (1154 of 
3653) of all ACE inhibitors or ARBs prescribed. Figure 2A 
shows the mean achieved doses (as a percentage of 
guideline-recommended dose) of ACE inhibitors or 
ARBs by country. The median prescribed dose was 33% 
(IQR 16–50%) of the guideline-recommended dose. 
Among the 11 countries, prescribed doses for ACE 
inhibitors or ARBs were highest in South Korea (87 [28%] 
of 312 people achieved guideline-recommended dose) 
and Indonesia (72 [28%] of 254; figure 2A). By contrast, 
prescribed doses were lowest in China (9 [2%] of 473), 
Thailand (6 [4%] of 166), and Japan (25 [5%] of 529; 
figure 2A). A full guideline-recommended dose of ACE 
inhibitors or ARBs was less common in older in-patients 
with longer length of stay, those with severe chronic 
kidney disease and atrial fibrillation (ptrend<0·001; table), 
and those in NYHA classes III and IV (data not shown).
Carvedilol (37%), bisoprolol fumarate (30%), and 
metoprolol (11%) were the most commonly prescribed 
β blockers. The median prescribed dose was 25% 
(IQR 13–50%) of the guideline-recommended dose, with 
65% of patients being prescribed doses that were less 
than 50% of guideline-recommended doses. There was 
regional variation in mean doses of β blocker (figure 2B), 
with the highest doses in Malaysia and Thailand. Japan 
had high uptake (91%) of β blockers (figure 1) but had 
the lowest achieved doses (figure 2B), with 41% of 
patients receiving less than 25% of the guideline-
recommended dose. Despite low doses of β blockers, 
mean heart rate was lowest in patients from Japan 
(72·6 beats per min [SD 14·1]); as expected, heart rates in 
Figure 2: Mean doses achieved by region
(A) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. (B) β blockers. (C) Mineralocorticoid 
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Observations 
available, n
Percentage achieved of guideline-recommended dose p value ptrend
0 1–24% 25–49% 50–99% ≥100%
Angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists
Number of participants 5005 1418 911 1074 992 610 ·· ··
Median age, years (IQR) 4991 62 (54–71) 60 (52–68) 60 (50–68) 59 (51–66) 60 (51–66) <0·001 <0·001
Female sex 5005 333 (23%) 192 (21%) 227 (21%) 209 (21%) 134 (22%) 0·523 0·233
Median body-mass index, kg/m² (IQR) 4799 23·8 (21·1–26·7) 23·7 (21·2–26·7) 24·2 (21·7–27·2) 25·0 (22·1–28·2) 24·8 (22·3–28·2) <0·001 <0·001
Median systolic blood pressure, mm Hg 
(IQR)
4983 117 (104–130) 110 (100–123) 116 (103–130) 120 (109–130) 120 (109–130) <0·001 <0·001
Median diastolic blood pressure, 
mm Hg (IQR)
4983 70 (63–80) 69 (60–78) 70 (63–80) 72 (67–80) 73 (65–81) <0·001 <0·001
Median heart rate, beats per min (IQR) 4979 78 (68–89) 76 (68–87) 78 (70–88) 78 (70–89) 78 (69–89) 0·016 0·096
Median LVEF, % (IQR) 5005 29% (23–34) 26% (20–33) 28% (22–33) 27% (22–33) 27% (22–32) <0·001 0·592
Ischemic cause of heart failure, n (%) 5000 660 (47%) 422 (46%) 511 (48%) 461 (47%) 270 (44%) 0·034 0·016
Enrolment type (in-patient status), n 
(%)
5004 819 (58%) 434 (48%) 418 (39%) 323 (33%) 174 (29%) <0·001 <0·001
Median length of stay, days (IQR) 2151 8·0 (4·0–14·0) 6·0 (3·0–14·0) 6·0 (3·0–11·0) 5·0 (3·0–10·0) 6·0 (3·0–11·0) <0·001 0·109
Medical history, n (%)
Coronary artery disease 4998 752 (53%) 456 (50%) 539 (50%) 476 (48%) 287 (47%) 0·073 0·005
Atrial fibrillation or flutter 4998 299 (21%) 229 (25%) 174 (16%) 123 (12%) 76 (12%) <0·001 <0·001
Hypertension 4997 785 (55%) 417 (46%) 524 (49%) 511 (52%) 341 (56%) <0·001 0·780
Peripheral arterial or vascular disease 4996 59 (4%) 46 (5%) 25 (2%) 28 (3%) 14 (2%) 0·002 0·002
Diabetes 4999 596 (42%) 339 (37%) 437 (41%) 400 (40%) 236 (39%) 0·200 0·362
Chronic kidney disease* 4004 676 (57%) 244 (40%) 263 (38%) 228 (36%) 158 (39%) <0·001 <0·001
Chronic obstructive pulmonary 
disease
4997 144 (10%) 66 (7%) 94 (9%) 70 (7%) 39 (6%) 0·012 0·003
Current or ex-smoker 4996 606 (43%) 451 (50%) 503 (47%) 431 (43%) 260 (43%) 0·002 0·792
Sinus rhythm 4758 852 (60%) 564 (62%) 742 (70%) 714 (72%) 449 (74%) <0·001 <0·001
Highest education level, n (%)
No formal education/Primary 1296 386 (28%) of 1338 183 (28%) of 664 272 (30%) of 897 288 (33%) of 878 167 (29%) of 569 <0·001 <0·001
Secondary 1600 477 (36%) of 1338 224 (34%) of 664 348 (39%) of 897 321 (37%) of 878 230 (41%) of 569 ·· ··
Pre-university (polytechnic, 
equivalent)
609 235 (18%) of 1338 98 (14%) of 664 116 (13%) of 897 97 (11%) of 878 63 (11%) of 569 ·· ··
Degree or higher 841 240 (18%) of 1338 159 (24%) of 664 161 (18%) of 897 172 (20%) of 878 109 (19%) of 569 ·· ··
β blockers
Number of participants 5061 1150 1325 1229 868 489 ·· ··
Median age, years (IQR) 5047 61 (53–71) 62 (53–70) 60 (51–68) 59 (51–67) 58 (49–66) <0·001 <0·001
Female sex 5061 286 (25%) 312 (24%) 235 (19%) 180 (21%) 95 (19%) 0·003 0·001
Median body-mass index, kg/m² (IQR) 4852 23·8 (21·2–26·7) 23·7 (21·0–26·6) 24·3 (21·8–27·3) 24·9 (22·2–28·3) 25·1 (22·3–28·2) <0·001 <0·001
Median systolic blood pressure, mm Hg 
(IQR)
5038 118 (102–130) 114 (102–129) 115 (105–130) 120 (106–131) 120 (107–133) <0·001 <0·001
Median diastolic blood pressure, 
mm Hg (IQR)
5038 70 (64–80) 70 (71–80) 70 (62–80) 71 (65–80) 71 (64–80) <0·001 <0·001
Median heart rate, beats per min (IQR) 5035 80 (70–94) 78 (69–88) 76 (68–87) 77 (68–86) 78 (69–87) <0·001 <0·001
Median LVEF, % (IQR) 5061 29% (23–29) 28% (21–33) 27% (21–33) 27% (22–34) 28% (22–33) <0·001 0·391
Ischemic cause of heart failure, n (%) 5056 544 (47%) 596 (45%) 605 (49%) 389 (45%) 229 (47%) 0·019 0·208
Enrolment type (in-patient status) 5060 555 (48%) 651 (49%) 491 (40%) 328 (38%) 164 (34%) <0·001 <0·001
Median length of stay, days (IQR) 2171 7·0 (4·0–13·0) 7·0 (3·0–13·0) 6·0 (3·0–12·0) 6·5 (4·0–12·0) 6·0 (3·0–11·0) 0·088 0·564
Medical history, n (%)
Coronary artery disease 5054 559 (49%) 654 (49%) 661 (54%) 419 (48%) 248 (51%) 0·062 0·311
Atrial fibrillation or flutter 5053 190 (17%) 234 (18%) 208 (17%) 175 (20%) 105 (22%) 0·045 0·011
Hypertension 5053 543 (47%) 655 (50%) 646 (53%) 476 (55%) 294 (60%) <0·001 <0·001
Peripheral arterial or vascular disease 5052 28 (2%) 60 (5%) 41 (3%) 27 (3%) 19 (4%) 0·065 0·509
(Table continues on next page)
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Japan were lower than in India, Indonesia, Taiwan, and 
Hong Kong (all >80 beats per min), where uptake of 
β blockers was lower than it was in Japan. Patients who 
achieved 100% or more of the guideline-recommended 
dose for β blockers were most often younger, in NYHA 
classes I and II (data not shown), and were more likely 
to have a high BMI, atrial fibrillation, diabetes, or 
hypertension (ptrend<0·001; table), but were less likely 
to be admitted to hospital or have clinical signs or 
symptoms of more severe heart failure (eg, peripheral 
Observations 
available, n
Percentage achieved of guideline-recommended dose p value ptrend
0 1–24% 25–49% 50–99% ≥100%
(Continued from previous page)
Diabetes 5055 454 (39%) 484 (37%) 511 (42%) 357 (41%) 239 (49%) <0·001 <0·001
Chronic kidney disease* 4051 436 (49%) 356 (39%) 358 (44%) 268 (44%) 169 (48%) <0·001 0·800
Chronic obstructive pulmonary disease 5053 139 (12%) 99 (7%) 85 (7%) 55 (6%) 27 (6%) <0·001 <0·001
Current or ex-smoker 5052 450 (39%) 604 (46%) 578 (47%) 398 (46%) 248 (51%) <0·001 <0·001
Sinus rhythm 4808 744 (65%) 872 (66%) 838 (68%) 577 (66%) 325 (66%) <0·001 <0·001
Highest education level, n (%)
No formal education/primary 1315 383 (35%) of 1096 321 (29%) of 1114 273 (27%) of 1003 214 (28%) of 737 124 (28%) of 427 <0·001 0·031
Secondary 1612 379 (35%) of 1096 409 (37%) of 1114 406 (40%) of 1003 266 (35%) of 737 152 (36%) of 427 ·· ..
Pre-university (polytechnic, 
equivalent)
605 133 (12%) of 1096 159 (14%) of 1114 145 (14%) of 1003 102 (14%) of 737 66 (15%) of 427 ·· ··
Degree or higher 845 201 (18%) of 1096 225 (20%) of 1114 179 (18%) of 1003 155 (21%) of 737 85 (19%) of 427 ·· ··
Mineralocorticoid receptor antagonists
Number of participants 5205 2279 156 813 1101 856 ·· ··
Median age, years (IQR) 5189 62 (54–71) 57 (52–64) 59 (51–68) 59 (51–67) 61 (52–69) <0·001 <0·001
Female sex 5205 520 (23%) 26 (17%) 149 (18%) 248 (23%) 200 (23%) 0·027 0·004
Median body-mass index, kg/m² (IQR) 4935 24·1 (21·6–27·3) 25·2 (22·6–28·3) 24·1 (21·3–27·0) 24·3 (21·6–27·3) 24·2 (21·7–27·3) <0·001 0·904
Median systolic blood pressure, mm Hg 
(IQR)
5143 120 (110–132) 117 (104–129) 114 (102–130) 115 (102–130) 119 (106–130) <0·001 <0·001
Median diastolic blood pressure, 
mm Hg (IQR)
5143 71 (64–80) 70 (60–80) 70 (62–80) 70 (62–80) 70 (64–80) <0·001 0·380
Median heart rate, beats per min (IQR) 5140 78 (69–88) 75 (67–86) 78 (68–89) 77 (68–88) 78 (70–88) 0·021 0·015
Median LVEF, % (IQR) 5205 29% (23–35) 25% (20–30) 27% (21–33) 27% (21–32) 27% (21–32) <0·001 0·503
Ischemic cause of heart failure, n (%) 5161 1192 (53%) 94 (61%) 381 (47%) 495 (45%) 264 (31%) <0·001 0·426
Enrolment type (in-patient status), n 
(%)
5203 1004 (44%) 88 (56%) 528 (65%) 395 (36%) 257 (30%) <0·001 <0·001
Median length of stay, days (IQR) 2246 6·0 (3·0–12·0) 4·0 (3·0–7·0) 7·0 (4·0–13·0) 6·0 (3·0–12·0) 8·0 (4·0–14·0) <0·001 <0·001
Medical history, n (%)
Coronary artery disease 5160 1215 (54%) 95 (61%) 387 (48%) 526 (48%) 359 (42%) <0·001 <0·001
Atrial fibrillation or flutter 5161 387 (17%) 20 (13%) 169 (21%) 230 (21%) 122 (14%) <0·001 0·015
Hypertension 5158 1292 (58%) 95 (61%) 416 (51%) 550 (50%) 320 (37%) <0·001 <0·001
Peripheral arterial or vascular disease 5160 80 (4%) 8 (5%) 43 (5%) 25 (2%) 21 (2%) 0·002 0·001
Diabetes 5160 987 (44%) 80 (52%) 300 (37%) 452 (41%) 264 (31%) <0·001 <0·001
Chronic kidney disease* 4132 879 (54%) 7 (41%) 194 (37%) 356 (41%) 167 (31%) <0·001 0·004
Chronic obstructive pulmonary 
disease
5161 194 (9%) 14 (9%) 81 (10%) 83 (8%) 59 (7%) 0·165 0·024
Current or ex-smoker 5158 1004 (45%) 96 (62%) 469 (58%) 497 (45%) 262 (31%) <0·001 <0·001
Sinus rhythm 4904 1483 (65%) 118 (76%) 571 (70%) 682 (62%) 561 (66%) <0·001 <0·001
Highest education level, n (%)
No formal education/Primary 1331 582 (30%) of 1921 3 (9%) of 32 184 (30%) of 613 303 (29%) of 1042 259 (31%) of 823 <0·001 0·132
Secondary 1639 677 (35%) of 1921 20 (63%) of 32 256 (42%) of 613 385 (37%) of 1042 301 (37%) of 823 ·· ··
Pre-university (polytechnic, 
equivalent)
614 252 (13%) of 1921 2 (6%) of 32 110 (18%) of 613 142 (14%) of 1042 108 (13%) of 823 ·· ··
Degree or higher 847 410 (21%) of 1921 7 (22%) of 32 63 (10%) of 613 212 (20%) of 1042 155 (19%) of 823 ·· ··
Some percentages do not sum to 100% because of rounding. LVEF=left ventricular ejection fraction. *Defined as an estimated glomerular filtration rate of less than 60 mL/min per 1·73 m². 
Table: Baseline characteristics by percentage achieved of guideline-recommended doses
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oedema, pulmonary rales; data not shown) or chronic 
obstructive pulmonary disorder.
Patients who achieved 100% of guideline-recommended 
dose for MRAs were more likely to be older, have higher 
systolic blood pressure, or be hypertensive (all ptrend<0·001), 
but less likely to have atrial fibrillation, diabetes, and 
chronic kidney disease (p<0·001; table). MRAs were 
prescribed in 2998 (58%) of 5205 patients. Spironolactone 
was the most commonly prescribed MRA (2845 [95%] of 
2998 patients on MRAs). Uptake of MRAs was highest in 
China (372 [78%] of 477) and lowest in Hong Kong (20 [40%] 
of 50) and Indonesia (112 [41%] of 272; figure 1). The 
median prescribed dose was 50% (IQR 40–100) of the 
guideline-recommended dose. Mean MRA doses were 
highest in India and Japan and lowest in Singapore 
(figure 2C). The overall prevalence of hyperkalaemia 
at recruitment was 2% cohort, with a higher propor-
tion of hyperkalaemia in non-MRA users (58 [3%] of 
1980 patients with serum potassium records) compared 
with those prescribed MRAs (41 [1%] of 2928, p=0·001). 
Follow-up data were available for 4544 (90%) of 
5061 eligible patients taking medication for heart 
failure, with median follow-up of 417 days (IQR 214–735). 
Compared with the reference group (0%, non-users), 
after adjustment, there was a dose-dependent reduction 
(ptrend≤0·001) of hazards of 1-year composite endpoint 
with increasing doses of ACE inhibitors or ARBs and 
β blockers (all p<0·001; figure 3). Patients who received 
at least 100% of guideline-recommended dose had 
better outcomes (hazard ratio [HR] 0·77, 95% CI 
0·72–0·81 for MRAs; HR 0·47, 0·46–0·50 for 
β blockers) than did those who received lower doses 
(figure 3). Notably, patients who achieved 50–99·9% of 
recommended doses for ACE inhibitors or ARBs had 
the best outcomes (0·44, 0·42–0·47; p<0·001 vs non-
users; figure 3). When compared with those who 
achieved at least 100% of recommended doses (in a 
separate sensitivity analysis), patients who achieved 
50–99·9% of recommended doses had a reduced 
hazard ratio (0·82, 0·76–0·89; p<0·001) for the 1-year 
combined endpoint. For MRAs, only doses above 50% 
of guideline-recommended doses were associated with 
a reduced hazard of the combined outcome (figure 3). 
The reduced HR (<1) in the 1–24·99% of guideline-
recommended dose of MRA could be due to chance or 
confounding, given the small size of this subgroup 
(156 patients vs ≥813 patients in other subgroups).
In multivariable models, patients with HFrEF from 
southeast Asia had almost double the risk of death at 
1 year (HR 1·9, 95% CI 1·4–2·6) compared with patients 
from northeast and south Asia. Although there was 
no interaction between region and outcomes for ACE 
inhibitors or ARBs and MRAs, region did modify the 
association between β blockers and combined outcome. 
β blockers at all doses were associated with reduced 
hazard of the combined outcome in northeast and south 
Asia, whereas only attainment of guideline-recommended 
dose of β blockers was associated with reduced hazard of 
the combined outcome in southeast Asia. Stratified HRs 
from the weighted model, however, showed no differences 
across regions, with the same beneficial pattern for all 
three therapeutic classes (appendix). 
We restricted our sensitivity analyses to non-imputed 
samples. The achievement of guideline-recommended 
dose for ACE inhibitors or ARBs (HR 0·22, 95% CI 
0·19–0·24), β blockers (0·13, 0·12–0·15), and MRAs 
(0·49, 0·45–0·53) remained associated with a survival 
benefit for the combined outcome. In sensitivity 
analyses restricted to outpatients, differences in uptake 
and doses between countries persisted. Outpatients that 
received at least 100% of guideline-directed medical 
therapy with ACE inhibitors or ARB (HR 0·56, 95% CI 
0·37–0·85) or β blockers (HR 0·48, 0·30–0·79) had a 
survival benefit for the primary combined outcome.
When all-cause mortality, cardiovascular mortality, and 
admittance to hospital because of heart failure at 1-year 
were examined separately, results for the composite 
outcome were similar (appendix).
Discussion
The ASIAN-HF registry provides real-world data on 
prescription of guideline-directed medical therapies in 
patients with HFrEF from 46 centres in 11 countries across 
Asia. There was substantial regional heterogeneity in the 
uptake and dose prescribing patterns of ACE inhibitors 
or ARBs, β blockers, and MRAs. Identified gaps in admini-
stration of guideline-directed medical therapies were 
monotherapy given instead of combined therapy and 
widespread underdosing, with recommended target doses 
achieved in only 17% of those given ACE inhibitors or 
ARBs, 13% of those given β blockers, and 29% of those 
given MRAs. Notably, there was a graded relationship 
between increased achieved doses of guideline-directed 
medical therapy and reduced risk of deaths or admittance 
to hospital because of heart failure. Even small doses 
(<25% of guideline-recommended dose) of ACE inhibitors 
or ARBs and β blockers were associated with improved 
Figure 3: Association of doses achieved with 1-year composite outcome of all-cause deaths or hospitalisation 
for heart failure
(A) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. (B) β blockers. (C) Mineralocorticoid 
receptor antagonists. Achieved doses were calculated as a percentage of the dose recommended by guidelines. 
We used inverse probability weighting to adjust for indication bias.
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outcomes compared with no dose or non-usage in the 
overall cohort. However, only attainment of guideline-
recommended dose of β blockers were associated with 
better outcomes in patients from southeast Asia, where 
outcomes are poor. Our findings support guideline 
recommendations to start evidence-based therapies in 
those who are not receiving any therapy, and to uptitrate 
the doses of ACE inhibitors or ARBs and β blockers to the 
maximum tolerated, to achieve maximum benefits in 
patients in Asia with HFrEF.
The widespread underdosing of ACE inhibitors or ARBs 
and β blockers found in our study is consistent with that 
reported in a pan-European study,6 despite encouraged 
uptitration, where full doses of guideline-directed medical 
therapy were achieved in 22% of patients given ACE 
inhibitors or ARB and in 12% for β blockers. The reduced 
proportion of patients achieving guideline-recommended 
doses of ACE inhibitor in our Asian cohort, compared 
with the European cohort, might be related to the higher 
prevalence of persistent cough with ACE inhibitor 
reported among people from Asia;10,24,25 although this 
reasoning would not explain differences in prescription of 
ARB. Additionally, in the ONTARGET study,26 a subgroup 
of Asians tolerated both telmisartan and ramipril better 
than non-Asians did, although the absolute risk of cough 
in Asians was higher (6·1% vs 3·9% in non-Asians) 
among those who discontinued ramipril. Patients in the 
European cohort had a mean age of 68 years (SD 12) and 
mean body-mass index of 28 kg/m² (5·5), thus were older 
and heavier than our Asian cohort. This finding suggests 
that underdosage of guideline-directed medical therapy 
in HFrEF could not be fully ascribed to the common 
perception that smaller body size was the dominant 
reason for low doses in Asians, since doses prescribed 
were similarly low in Europeans of larger body size.
Despite similarities in the underutilisation of guideline-
directed medical therapy worldwide, geographical region 
within Asia had the most pronounced association with 
variation in attainment of recommended doses of 
guideline-directed medical therapy in ASIAN-HF. We 
were unable to determine the reasons for the differences 
in prescription patterns but made some notable 
observations with regards to regional socioeconomic 
status. For uptake of guideline-directed medical therapy, 
patients in high-income countries—such as Singapore, 
Hong Kong, Korea, and Japan—were more likely to be 
prescribed dual first-line medications compared with 
lower income countries, consistent with PURE27 and 
INTER-CHF;28 however, socioeconomic status did not 
affect uptitration of guideline-directed medical therapy, 
and patients in Japan were prescribed the lowest doses of 
β blockers whereas those in lower income regions, such 
as India and Thailand, were prescribed the highest doses. 
Patients’ educational status was not predictive of 
attainment of guideline-recommended dose; we speculate 
that physician factors or country-specific factors (eg, 
differences in health-care systems, local manufacturing 
capability, health policies, delivery and quality of cardiac 
care) might have influenced prescription patterns. 
Notably, the high uptake of spironolactone in China 
could be attributed to a nationwide quality assessment 
evaluation programme,29 presumably driven partly by the 
low cost of spironolactone (US$0·08 per day).
The case for achieving target high doses of ACE 
inhibitors or ARB in HFrEF has been established from 
prospective clinical trials, albeit not specifically among 
patients in Asia. The HEAAL trial30 compared low-dose 
versus high-dose (50 mg vs 150 mg; 33–100% of guideline-
recommended doses) losartan potassium in patients 
with HFrEF and reported that high-dose losartan 
potassium favoured a combined endpoint of all-cause 
mortality or admittance to hospital because of heart 
failure (p=0·027). In the ATLAS trial,31 over 46 months of 
follow up, high doses of lisinopril, 32·5–35·0 mg/day 
(93–100% of guideline-recommended doses), led to a 
significant reduction (12%) in the composite outcome of 
death or admittance to hospital because of heart failure 
compared with low doses of 2·5–5·0 mg/day of lisinopril 
(7–14% of guideline-recommended dose). According 
to 2016 European Society of Cardiology guidelines,1 
the recommended initial dose of carvedilol in the 
management of HFrEF is 6·25 mg/day, uptitrating to 
50 mg/day as maintenance if tolerated. Reduced doses 
were tested in the Japanese randomised, placebo-
controlled double blind MUCHA trial,32 where carvedilol 
at doses of 5–20 mg/day led to reductions of 71–91% in 
risk of death or admittance to hospital because of 
heart failure or cardiovascular event, albeit to a smaller 
extent than did 20 mg/day. In another study among 
Japanese patients with dilated cardio myopathy, a mean 
maintenance dose of 14 mg/day (SD 7) carvedilol 
increased LVEF from 28% (SD 7) to 39% (9) over 
6 months,33 consistent with the benefits reported by 
MUCHA.32 These results are also consistent with our 
observation of graded survival benefit with higher doses 
of β blockers, even at low doses (<25–50% guideline-
recommended dose).
The use of MRAs to treat HFrEF is well established.1,34 
Our findings showed low doses of MRAs (<50%) were 
associated with more harm than was seen in those who 
did not receive MRAs, suggesting a possible threshold 
effect of higher doses, but perhaps also reflecting the 
frailer nature of patients who are unable to tolerate full 
doses of MRA. Our observational study was not designed 
to investigate the dose-dependent effects of MRAs. 
Although prevalence of hyperkalaemia was low in our 
cohort, more research is needed to define MRA-associated 
risks in Asia, particularly in light of the low cost of 
spironolactone and its uniquely high use in China.
We acknowledge that observational data cannot 
definitively establish causality or drug efficacy. 
Randomised controlled trials are required for definitive 
answers. Although we used inverse probability weighting 
to account for potential bias by indication, residual 
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confounding of unmeasured factors might affect our 
results. Furthermore, our data is observational and 
might be affected by possible selection bias with regard 
to the centres invited to partici pate and is, for this 
reason, hypothesis-generating rather than comprehensive 
regional data. Priority was given to sites that could provide 
high-quality data with as little missing data as possible. 
Although our data does not include population-based 
data throughout the 11 Asian regions examined in ASIAN-
HF, every effort was made to minimise loss to follow-up, 
and our approach probably represents the best practice 
that could be feasibly achieved in our multinational 
observational registry. Given all the constraints of the 
large geographical areas with diverse socioeconomic 
factors and availability of health care, our data represent a 
best case scenario that underestimates the broader 
deficiencies in medical prescribing in each region. We 
further acknowledge our lack of data on adherence to 
medications. In the absence of any other such real-world 
evidence from a large multinational Asian population, 
the current data and findings are probably the best 
available evidence for clinicians caring for HFrEF in Asia.
Our findings suggest the need for interventions to 
increase the prescribing rates or initiation of first-
line guideline-directed medical therapy in Asians with 
HFrEF, particularly those in low-income and middle-
income countries. Strategies that warrant consideration 
include the establishment of programmatic approaches 
to the management of heart failure, targeted education 
for physicians to strengthen evidence-based practices, 
provision of initiatives in populous Asia to support 
overworked physicians with an excessive number of cases, 
and increased patient awareness of the importance of 
guideline-directed medical therapy at targeted doses.
In summary, we observed substantial regional variation 
in guideline-directed medical therapy and uptake among 
patients with HFrEF across Asia. Identified gaps in 
admin i stration of such therapy were monotherapy 
(instead of combined therapy) and widespread under-
dosing of medications. Increased achieved doses of ACE 
inhibitors or ARBs and β blockers were associated with 
improved outcomes, as we expected. Although smaller 
doses of ACE inhibitors or ARBs and β blockers conferred 
some benefit, guideline-recommended doses led to 
maximum benefit. These first prospective multi national 
data from Asia suggest that efforts to improve uptake and 
uptitration of guideline-directed medical therapies are 
warranted.
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